Cited 0 times in
Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김용배 | - |
dc.contributor.author | 장지석 | - |
dc.date.accessioned | 2021-12-28T17:15:29Z | - |
dc.date.available | 2021-12-28T17:15:29Z | - |
dc.date.issued | 2021-06 | - |
dc.identifier.issn | 2234-1900 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187012 | - |
dc.description.abstract | Purpose: This study was conducted to evaluate prognosis of patients with level I/II axillary lymph node metastases from occult breast cancer (OBC). Materials and methods: Data of 53 patients with OBC who received axillary lymph node dissection (ALND) positive/negative (+/-) breast-conserving surgery between 2001 and 2013 were retrospectively collected at seven hospitals in Korea. The median number of positive lymph nodes (+LNs) was 2. Seventeen patients (32.1%) had >3 +LNs. A total of 48 patients (90.6%) received radiotherapy. Extents of radiotherapy were as follows: whole-breast (WB; n = 11), regional lymph node (RLN; n = 2), and WB plus RLN (n = 35). Results: The median follow-up time was 85 months. Recurrence was found in four patients: two in the breast, one in RLN, and one in the breast and RLN. The 5-year and 7-year disease-free survival (DFS) rates were 96.1% and 93.5%, respectively. Molecular subtype and receipt of breast radiotherapy were significantly associated with DFS. Patients with estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative (ER-/PR-/HER2-) subtype had significantly lower 7-year DFS than those with non-ER-/PR-/HER2- tumor (76.9% vs. 100.0%; p = 0.03). Whole breast irradiation (WBI) was significantly associated with a higher 7-year DFS rate (94.7% for WBI group vs. 83.3% for non-WBI group; p = 0.01). Other factors including patient's age, number of +LNs, taxane chemotherapy, and RLN irradiation were not associated with DFS. Conclusion: Patients with OBC achieved favorable outcome after ALND and breast-targeting treatment. Molecular subtype and receipt of WBI was significant factors for DFS. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Society for Therapeutic Radiology and Oncology | - |
dc.relation.isPartOf | RADIATION ONCOLOGY JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Haeyoung Kim | - |
dc.contributor.googleauthor | Won Park | - |
dc.contributor.googleauthor | Su SSan Kim | - |
dc.contributor.googleauthor | Sung Ja Ahn | - |
dc.contributor.googleauthor | Yong Bae Kim | - |
dc.contributor.googleauthor | Tae Hyun Kim | - |
dc.contributor.googleauthor | Jin Hee Kim | - |
dc.contributor.googleauthor | Jin-Hwa Choi | - |
dc.contributor.googleauthor | Hae Jin Park | - |
dc.contributor.googleauthor | Jee Suk Chang | - |
dc.contributor.googleauthor | Doo Ho Choi | - |
dc.identifier.doi | 10.3857/roj.2021.00241 | - |
dc.contributor.localId | A00744 | - |
dc.contributor.localId | A04658 | - |
dc.relation.journalcode | J02592 | - |
dc.identifier.eissn | 2234-3164 | - |
dc.identifier.pmid | 34619827 | - |
dc.subject.keyword | Breast neoplasm | - |
dc.subject.keyword | Lymph nodes | - |
dc.subject.keyword | Radiotherapy | - |
dc.subject.keyword | Unknown primary neoplasms | - |
dc.contributor.alternativeName | Kim, Yong Bae | - |
dc.contributor.affiliatedAuthor | 김용배 | - |
dc.contributor.affiliatedAuthor | 장지석 | - |
dc.citation.volume | 39 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 107 | - |
dc.citation.endPage | 112 | - |
dc.identifier.bibliographicCitation | RADIATION ONCOLOGY JOURNAL, Vol.39(2) : 107-112, 2021-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.